Research questions new Medtronic stent

The Endeavor stent, which Medtronic hopes can hold on to a respectable chunk of the $4 billion worldwide stent market, leads to more complications than rival devices and doesn’t reduce the need for future treatment, according to research presented at a conference yesterday. But the researchers cautioned that the study patients have only been followed for nine months so far, and Endeavor may have been placed into patients who were sicker to start with. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.